On 21 August 2020, orphan designation EU/3/20/2321 was granted by the European Commission to Vivet Therapeutics S.A.S., France, for adeno-associated viral vector serotype 3B encoding shortened human ATP7B (also known as VTX-801) for the treatment of Wilson’s disease.
Adeno-associated viral vector serotype 3B encoding shortened human ATP7B
|Disease / condition||
Treatment of Wilson's disease
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.